



STATE OF TENNESSEE

2021 Episodes of Care Results

Results of Episodes of Care Program

CY 2015	CY 2016	CY 2017	CY 2018	CY 2019
<p><i>Estimated Savings*:</i> \$10.8 million</p> <ul style="list-style-type: none"> Providers and hospitals reduced costs while maintaining quality of care Gain sharing payments to providers exceeded risk sharing payments by \$280,000 <p>Includes the 3 episodes in performance in CY 2015</p>	<p><i>Estimated Savings*:</i> \$14.5 million</p> <ul style="list-style-type: none"> Quality metrics improved for perinatal, total joint replacement, and COPD, and were mostly maintained for the remaining episodes Gain sharing payments to providers exceeded risk sharing payments by \$395,000 <p>Includes the 8 episodes in performance in CY 2016</p>	<p><i>Estimated Savings*:</i> \$28.6 million</p> <ul style="list-style-type: none"> Quality metrics improved or maintained for most episodes Gain sharing payments to providers exceeded risk sharing payments by \$206,900 <p>Includes the 19 episodes in performance in CY 2017</p>	<p><i>Estimated Savings*:</i> \$38.3 million</p> <ul style="list-style-type: none"> Quality metrics improved or maintained for most episodes Gain sharing payments to providers exceeded risk sharing payments by \$686,000 <p>Includes the 27 episodes in performance in CY 2018</p>	<p><i>Estimated Savings*:</i> \$45.2 million</p> <ul style="list-style-type: none"> Quality metrics improved or maintained for most episodes Gain sharing payments totaled \$1.9 million Due to COVID-19, all risk sharing payments have been waived for the 2019 performance period <p>Includes the 45 episodes in performance in CY 2019</p>

*Compared to 3% projected medical cost trend

COVID-19 and 2021 Episodes of Care Results

Due to the ongoing COVID-19 pandemic, estimated savings will not be calculated for the Calendar Year (CY) 2021 performance period.

The state recognizes that COVID-19 continues to be an unprecedented health and economic crisis for the provider community. In order to continue to support providers during this difficult time, the three TennCare Managed Care Organizations (MCOs) waived all episodes of care risk sharing payments for the 2019, 2020 and 2021 performance years. Providers who have gain sharing payments in their final 2021 performance reports will receive those payments as planned, with no changes. For 2021, gain sharing payments totaled **\$1.4 million**.



QUALITY PERFORMANCE

Episode Gain Sharing Quality Metrics – Wave 1

Wave 1 Episodes*	CY 2014	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY2021	Target Performance
Perinatal (17,671 valid episodes)									
1. HIV Screening (≥ 90%)	90.2%	88.3%	87.7%	89.1%	92.8%	94.6%	91.5%	87.2%	Higher is better
2. Group B Streptococcus Screening (≥ 90%)	87.8%	85.9%	94.0%	95.5%	95.2%	96.7%	92.7%	92.1%	Higher is better
3. C-Section Rate (≤ 38%)	30.5%	31.6%	30.6%	31.2%	30.8%	29.9%	29.6%	29.7%	Lower is better
Acute Asthma Exacerbation (7,266 valid episodes)									
1. Follow-up Visit with Physician (≥ 30%)	N/A	N/A**	29.6%	30.3%	32.4%	30.8%	27.4%	30.6%	Higher is better
2. Patient on Appropriate Medication (≥ 60%)	N/A	N/A**	60.3%	65.4%	69.5%	66.8%	62.8%	61.5%	Higher is better
Total Joint Replacement (146 valid episodes)									
1. Admission Within the Post-Trigger Window 1 (≥ 10%)	N/A	N/A	N/A	N/A	N/A***	2.0%	3.1%	0.7%	Lower is better

*Valid episodes in 2021 performance period across all three MCOs
 **There was a coding change to these quality metrics so there is no direct comparison
 ***There was not a quality metric tied to gain sharing for this episode until the 2020 performance period.



Episode Gain Sharing Quality Metrics – Wave 2

Wave 2 Episodes*	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY2021	Target Performance
Cholecystectomy (1,325 valid episodes)								
1. Hospitalization in Post-Trigger Window ($\leq 10\%$)	0.8%	1.0%	0.9%	0.3%	0.2%	0.3%	0.3%	<i>Lower is better</i>
COPD (1,734 valid episodes)								
1. Follow-up Care Within Post-Trigger Window ($\geq 45\%$)	45.1%	46.7%	47.4%	46.7%	48.1%	44.6%	44.6%	<i>Higher is better</i>
Acute PCI (134 valid episodes)								
1. Hospitalization in Post-Trigger Window ($\leq 10\%$)	1.0%	0.7%	0.7%	1.1%	0.9%	0.0%	0.7%	<i>Lower is better</i>
Non-acute PCI (45 valid episodes)								
1. Hospitalization in Post-Trigger Window ($\leq 10\%$)	0.0%	1.6%	0.0%	0.0%	0.0%	0.0%	0.0%	<i>Lower is better</i>

Note: There are no quality metrics tied to gain sharing for the colonoscopy episode
 *Valid episodes in 2021 performance period across all three MCOs



Episode Gain Sharing Quality Metrics – Wave 3

Wave 3 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
GI Hemorrhage (712 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 45%)	49.0%	51.9%	50.1%	50.0%	47.7%	47.6%	Higher is better
Pneumonia (1,548 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	N/A	N/A**	30.4%	30.4%	29.3%	27.9%	Higher is better
UTI-Inpatient (631 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 40%)	46.0%	43.5%	42.4%	41.1%	43.8%	41.5%	Higher is better
UTI-Outpatient (26,679 valid episodes)							
1. Admission Within the Trigger Window for ED Triggered Episodes (≤ 5%)***	5.6%	6.1%	7.0%	6.3%	7.3%	6.7%	Lower is better
2. Admission Within the Trigger Window for Non-ED Triggered Episodes (≤ 5%)***	0.8%	1.0%	1.0%	1.0%	0.9%	0.7%	Lower is better
Respiratory Infection (253,321 valid episodes)							
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A	N/A	N/A****	2.6%	2.2%	1.7%	Lower is better
EGD (5,564 valid episodes)							
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A	N/A	N/A****	4.0%	4.0%	3.4%	Lower is better

*Valid episodes in 2021 performance period across all three MCOs

**There was a coding change to these quality metrics so there is no direct comparison

***This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

****There was not a quality metric tied to gain sharing for this episode until the 2019 performance period



Episode Gain Sharing Quality Metrics – Wave 4

Wave 4 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Bariatric Surgery (482 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	35.6%	37.4%	43.3%	43.0%	42.2%	45.0%	Higher is better
CHF Acute Exacerbation (1,637 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 60%)	56.2%	57.2%	57.0%	56.0%	54.6%	54.1%	Higher is better
ODD (1,278 valid episodes)							
1. Minimum Care Requirement (≥ 30%)	26.7%	35.8%	31.9%	30.7%	34.4%	33.8%	Higher is better
CABG (39 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	71.4%	70.0%	78.5%	81.6%	88.3%	74.4%	Higher is better
Valve Repair and Replacement (5 valid episodes)							
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	78.5%	77.7%	76.7%	100.0%	63.6%	40.0%	Higher is better
ADHD (20,934 valid episodes)							
1. Minimum Care Requirement (≥ 70%)	N/A**	78.5%	78.8%	77.6%	74.0%	76.2%	Higher is better
2. Long-acting Stimulants for Members Aged 6 to 11 Years (≥ 80%)***	N/A**	83.1%	82.9%	83.6%	80.7%	80.6%	Higher is better
3. Long-acting Stimulants for Members Aged 12 to 20 Years (≥ 80%)***	N/A**	83.0%	83.1%	83.9%	82.7%	80.1%	Higher is better
4. Utilization of Therapy for Members Aged 4 and 5 Years (1 visit)***	N/A**	1.42	1.71	1.60	1.24	1.04	Higher is better

*Valid episodes in 2021 performance period across all three MCOs

**The preview period for the ADHD episode was 2017. The initial performance period for the ADHD episode was 2018

*** This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



Episode Gain Sharing Quality Metrics – Wave 5

Wave 5 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Breast Biopsy (575 valid episodes)						
1. Appropriate Diagnostic Workup Rate ($\geq 90\%$)	82.8%	80.8%	85.1%	83.5%	90.6%	<i>Higher is better</i>
2. Core Needle Biopsy Rate ($\geq 85\%$)**	77.5%	82.2%	92.0%	92.0%	91.3%	<i>Higher is better</i>
Tonsillectomy (3,252 valid episodes)						
1. Bleeding Up to Two Days Following the Procedure ($\leq 5\%$)	0.7%	0.5%	0.7%	0.7%	0.9%	<i>Lower is better</i>
Otitis Media (88,094 valid episodes)						
1. Otitis Media with Effusion (OME) Episodes without Antibiotics Filled ($\geq 25\%$)**	27.7%	26.2%	31.6%	35.2%	29.5%	<i>Higher is better</i>
2. Non-OME Episodes with Amoxicillin ($\geq 60\%$)**	64.3%	66.9%	65.1%	63.7%	66.0%	<i>Higher is better</i>

*Valid episodes in 2021 performance period across all three MCOs

** This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



Episode Gain Sharing Quality Metrics – Wave 6

Wave 6 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Skin and Soft Tissue Infection (32,812 valid episodes)						
1. Bacterial Cultures when Incision and Drainage Performed (≥ 50%)**	42.4%	42.5%	40.7%	42.4%	43.3%	Higher is better
2. SSTI Episodes with a First Line Antibiotic (≥ 85%)**	97.7%	97.8%	98.0%	97.6%	97.8%	Higher is better
HIV (579 valid episodes)						
1. Periodic anti-retroviral therapy (ART) refill (≥ 85%)	71.6%	73.1%	73.8%	75.8%	69.8%	Higher is better
Diabetes Acute Exacerbation (561 valid episodes)						
1. Follow-up care in the first 14 days of the post-trigger window (≥ 30%)	25.4%	30.6%	30.3%	27.9%	28.3%	Higher is better
Pancreatitis (456 valid episodes)						
1. Follow-up care in the first 14 days of the post-trigger window (≥ 35%)	31.9%	35.8%	30.7%	32.9%	30.0%	Higher is better

*Valid episodes in 2021 performance period across all three MCOs

** This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



Episode Gain Sharing Quality Metrics – Wave 7

Wave 7 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Spinal Fusion (266 valid episodes)					
1. Difference in Average MED/Day (≤ 8.0)	0.04	4.26	2.17	5.06**	Lower is better
Spinal Decompression (81 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	1.38	5.71	1.40	-1.10	Lower is better
Femur/Pelvic Fracture (98 valid episodes)					
1. Related follow-up care ($\geq 30\%$)	6.8%	9.6%	7.0%	5.1%	Higher is better
2. Difference in Average MED/Day (≤ 8.0)	2.00	0.97	10.03	-7.44	Lower is better
Knee Arthroscopy (795 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	-0.96	0.66	-0.47	0.30	Lower is better
Non-operative Ankle Injury (12,618 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	0.02	0.38	0.87	0.09	Lower is better
Non-operative Wrist Injury (6,903 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	0.11	0.47	0.19	0.96	Lower is better
Non-operative Shoulder Injury (6,067 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	0.45	0.78	1.37	0.75	Lower is better
Non-operative Knee Injury (6,653 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	0.73	0.05	1.01	0.76	Lower is better
Back/Neck Pain (35,920 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	1.98	2.28	4.58	3.40	Lower is better

*Valid episodes in 2021 performance period across all three MCOs

**This quality metric is based on a formula related to opioid prescriptions. The increase for these metrics was driven by a few episode outliers that are being investigated and addressed by the Managed Care Organizations and aligned with TennCare’s overall opioid strategy. For more information on TennCare’s Opioid Strategy, please visit the following



website - <https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

Episode Gain Sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Acute Seizure (4,764 valid episodes)					
1. Brain MRI Utilization in Focal Epilepsy ($\geq 10\%$)**	18.0%	18.7%	18.3%	16.1%	Higher is better
2. Prolonged EEG Monitoring Utilization in Newly Diagnosed Seizure ($\geq 10\%$)**	7.4%	5.7%	2.8%	2.2%	Higher is better
Syncope (5,166 valid episodes)					
1. Carotid Ultrasound Imaging in Adults ($\leq 10\%$)**	5.8%	4.0%	3.7%	3.4%	Lower is better
Bronchiolitis (4,204 valid episodes)					
1. Related Admission during the Post-Trigger Window ($\leq 10\%$)	1.1%	1.1%	0.8%	0.7%	Lower is better
2. Utilization of Bronchodilators ($\leq 30\%$)	14.4%	16.9%	13.0%	14.6%	Lower is better
3. Utilization of Steroids ($\leq 50\%$)	22.0%	22.4%	20.4%	22.7%	Lower is better
Pediatric Pneumonia (1,538 valid episodes)					
1. Related Admission during the Post-Trigger Window ($\leq 10\%$)	1.3%	1.2%	0.6%	0.9%	Lower is better
2. Utilization of Macrolides in Patients Under 6 Years Old ($\leq 30\%$) **	19.7%	20.7%	18.2%	17.0%	Lower is better
3. Utilization of Narrow Spectrum Antibiotics ($\geq 50\%$)	52.0%	57.6%	56.7%	61.8%	Higher is better

*Valid episodes in 2021 performance period across all three MCOs

** This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



Episode Gain Sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	Target Performance
Colposcopy (2,690 valid episodes)					
1. LEEP Utilization Under 26 Years Old With No Evidence of High Grade Dysplasia ($\leq 10\%$)**	4.2%	4.2%	1.9%	1.6%	Lower is better
2. LEEP Utilization with Low-grade Dysplasia ($\leq 10\%$)**	9.5%	7.0%	11.0%	13.2%	Lower is better
Hysterectomy (686 valid episodes)					
1. Alternative Treatments ($\geq 20\%$)	31.0%	34.2%	43.7%	45.8%	Higher is better
2. Related Follow-up Care ($\geq 10\%$)	19.2%	20.1%	22.2%	33.8%	Higher is better
GI Obstruction (153 valid episodes)					
1. Related Follow-up Care ($\geq 20\%$)	33.0%	32.6%	35.6%	34.0%	Higher is better
2. Difference in Average MED/Day (≤ 1.0)	4.13	3.31	3.53	4.08	Lower is better
Appendectomy (867 valid episodes)					
1. Abdominopelvic CT Scans in Children ($\leq 50\%$)**	42.4%	36.9%	39.2%	36.7%	Lower is better
1. Difference in Average MED/Day (≤ 1.0)	-0.21	-0.09	1.55	-0.06	Lower is better
Hernia Repair (1,130 valid episodes)					
1. Difference in Average MED/Day (≤ 1.0)	0.12	0.63	1.39	-1.11	Lower is better
Acute Gastroenteritis (16,279 valid episodes)					
1. Abdominopelvic CT or MRI in Adults ($\leq 40\%$)**	N/A	41.1%	45.3%	47.5%	Higher is better
2. Abdominopelvic CT or MRI in Children ($\leq 40\%$)**	N/A	4.7%	6.8%	6.2%	Higher is better
3. Antibiotics Utilization ($\leq 30\%$)	N/A	21.9%	24.1%	21.8%	Higher is better

*Valid episodes in 2021 performance period across all three MCOs

** This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



Episode Gain Sharing Quality Metrics – Wave 9

Wave 9 Episodes*	CY 2019	CY 2020	CY 2021	Target Performance
Cystourethroscopy (1,203 valid episodes)				
1. Difference in Average MED/Day (≤ 1.0)	0.35	-0.22	0.90	<i>Lower is better</i>
2. Related ED Visit ($\leq 10\%$)	5.4%	5.6%	3.4%	<i>Lower is better</i>
3. Repeat cystourethroscopy ($\leq 5\%$)	2.8%	2.6%	4.3%	<i>Lower is better</i>
Acute Kidney and Ureter Stones (1,733 valid episodes)				
1. Difference in Average MED/Day (≤ 3.0)	2.49	3.16	1.03	<i>Lower is better</i>
2. Related ED Visit ($\leq 15\%$)	18.9%	16.0%	15.8%	<i>Lower is better</i>

*Valid episodes in 2021 performance period across all three MCOs

